Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database.

Abstract:

OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively studied. METHODS:Retrospective analyses of the Truven Health MarketScan database (2006-2012) aimed to quantify drug and resource utilization in pregnant women with lupus, as well as the incidence of pregnancy complications in these patients. Records of women aged 12-54 were reviewed and both lupus patients and pregnancies identified. Pregnant women with lupus were matched 1:5 with either pregnant women without lupus, or non-pregnant women with lupus. RESULTS:Pregnancies with lupus were associated with increased complications when compared to pregnancies without lupus. During pregnancy, the use of immunosuppressants decreased in pregnant women with lupus, as did rheumatologist visits, while the number of women not treated with any immunosuppressant increased. Pregnant women with lupus showed higher overall treatment costs than controls. However, compared to non-pregnant women with lupus, medication costs actually dropped, possibly due to the withdrawal of medications from these patients or women becoming pregnant while disease activity was low. CONCLUSIONS:The large database analyses reported here revealed that pregnancies in women with lupus were associated with a higher risk of complications, higher healthcare costs, and fewer prescribed medications, including immunosuppressants, than the control groups. The increased risk of complications and decreased immunosuppressant use suggest that patients require additional guidance from physicians to give them the best chance of experiencing a safe pregnancy. Indeed, despite the recognized role active lupus plays in increasing pregnancy complications, women with lupus had fewer rheumatology visits during pregnancy, although their visits to their general practitioner/primary healthcare provider increased, highlighting the need for team-based co-ordination care between OBGYN physicians and rheumatologists.

journal_name

J Med Econ

authors

Petri M,Daly RP,Pushparajah DS

doi

10.3111/13696998.2015.1066796

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

967-73

issue

11

eissn

1369-6998

issn

1941-837X

journal_volume

18

pub_type

杂志文章
  • The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

    abstract:INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1580200

    authors: Seetasith A,Wong W,Tse J,Burudpakdee C

    更新日期:2019-05-01 00:00:00

  • The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine.

    abstract:BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...

    journal_title:Journal of medical economics

    pub_type: 评论,社论

    doi:10.3111/13696998.2015.1073736

    authors: Godman B

    更新日期:2015-01-01 00:00:00

  • Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

    abstract:OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.690801

    authors: Copher R,Cerulli A,Watkins A,Laura Monsalvo M

    更新日期:2012-01-01 00:00:00

  • Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).

    abstract:OBJECTIVE:To characterize patient and physician satisfaction with current standard-of-care botulinum toxin treatment regimens for symptom control in patients with post-stroke spasticity using structured interviews with patients and physicians. RESEARCH DESIGN AND METHODS:Two cross-sectional surveys were conducted in C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.925462

    authors: Bensmail D,Hanschmann A,Wissel J

    更新日期:2014-09-01 00:00:00

  • Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.

    abstract:INTRODUCTION:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.903257

    authors: Gimenez E,Besses C,Boque C,Velez P,Kerguelen A,Cervantes F,Ferrer-Marin F,Perez-Encinas M,Rodriguez M,Gonzalez JD,Calzada R,Hernandez-Boluda JC

    更新日期:2014-06-01 00:00:00

  • The cost to managed care of managing pulmonary hypertension.

    abstract:OBJECTIVE:To estimate direct medical costs and resource use for commercially-insured patients within two pulmonary hypertension sub-groups: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). RESEARCH DESIGN AND METHODS:Using a retrospective cohort design, subjects (≥18 yea...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.665109

    authors: Said Q,Martin BC,Joish VN,Kreilick C,Mathai SC

    更新日期:2012-01-01 00:00:00

  • Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.

    abstract:OBJECTIVE:To study outcomes of multiple sclerosis (MS) patients treated with either glatiramer acetate (Copaxone) or interferon beta-1a for once-weekly, intramuscular administration (Avonex). METHODS:An 'intent-to-treat' (ITT) cohort (n=1282) was established, consisting of patients diagnosed with MS who began therapy ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.496650

    authors: Castelli-Haley J,Oleen-Burkey MA,Lage MJ,Johnson K

    更新日期:2010-01-01 00:00:00

  • Correlation between gross domestic product, utilization of in vitro fertilization, and pregnancy success rate across the world.

    abstract::Background: IVF is now a wide spread procedure globally, and currently 65 countries report annually all or part of their IVF/ICSI cycles, from which the International Committee Monitoring progress in Assisted Reproduction Technology (ICMART) published its report. There is considerable variation in the utilization (num...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1609484

    authors: Lass A,Chaudary W,Lass G

    更新日期:2019-09-01 00:00:00

  • The economic burden of chronic obstructive pulmonary disease from 2004 to 2013.

    abstract:OBJECTIVES:This study examines the epidemiology and economic impact of chronic obstructive pulmonary disease (COPD) at a nationwide level in South Korea. METHODS:This retrospective analysis used the societal cost-of-illness framework, consisting of direct medical costs, direct non-medical costs, and indirect costs. In...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1100114

    authors: Kim J,Lee TJ,Kim S,Lee E

    更新日期:2016-01-01 00:00:00

  • How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?

    abstract:BACKGROUND:Efficient use of government funding has been increasingly relevant for the success and sustainability of ongoing health-system reform in China; however, as there is no generic substitution policy, patients and basic health-insurance programs pay more for public-preferred brand originators. Such phenomenon is...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1181641

    authors: Sun J,Ren L,Wirtz V

    更新日期:2016-09-01 00:00:00

  • Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.

    abstract::Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1757456

    authors: Pruis SL,Jeon YK,Pearce F,Thong BY,Aziz MIA

    更新日期:2020-08-01 00:00:00

  • Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.

    abstract:AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1363766

    authors: Jacobs MS,van Leent MWJ,Tieleman RG,Jansman FGA,Cao Q,Postma MJ,van Hulst M

    更新日期:2017-12-01 00:00:00

  • Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine.

    abstract:OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990902949614

    authors: Bretzel RG,Dippel FW,Linn T,Neilson AR

    更新日期:2009-06-01 00:00:00

  • Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

    abstract:OBJECTIVE:To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS:A semi-Markov model was developed...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/13696998.2017.1285780

    authors: Rivera F,Valladares M,Gea S,López-Martínez N

    更新日期:2017-06-01 00:00:00

  • A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.

    abstract:OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.675890

    authors: Pollock RF,Curtis BH,Valentine WJ

    更新日期:2012-01-01 00:00:00

  • Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.

    abstract:PURPOSE:The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots. METHODS:An existing 1-year decision-analytic framework was adapted to model drug use in t...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.820193

    authors: Einarson TR,Zilbershtein R,Skoupá J,Veselá S,Garg M,Hemels ME

    更新日期:2013-09-01 00:00:00

  • A societal cost-of-illness study of hemodialysis in Lebanon.

    abstract:AIM:Renal failure is a growing public health problem, and is mainly treated by hemodialysis. This study aims to estimate the societal costs of hemodialysis in Lebanon. METHODS:This was a quantitative, cross-sectional cost-of-illness study conducted alongside the Nutrition Education for Management of Osteodystrophy tri...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1207653

    authors: Rizk R,Hiligsmann M,Karavetian M,Salameh P,Evers SM

    更新日期:2016-12-01 00:00:00

  • Cost of operating room time for endovascular transcatheter aortic valve replacement.

    abstract::Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1627364

    authors: Potter BJ,Ann Thompson C

    更新日期:2019-10-01 00:00:00

  • Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.

    abstract:OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.770747

    authors: Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

    更新日期:2013-01-01 00:00:00

  • Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.

    abstract:AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1532905

    authors: Igarashi A,Igarashi A,Graham CN,Gilloteau I,Tani Y

    更新日期:2018-10-26 00:00:00

  • Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study.

    abstract:OBJECTIVE:To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA). METHODS:This retrospective cohort study selected patients who had SEGA surgery and TSC claims between 2000-2011 from three large US nationwide claims datab...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.1001513

    authors: Sun P,Liu Z,Krueger D,Kohrman M

    更新日期:2015-05-01 00:00:00

  • Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.

    abstract:BACKGROUND:Growing financial pressure on US dialysis providers requires economic efficiency considerations. The objective of this study was to examine short-term economic efficiencies of a cinacalcet-based treatment approach for secondary hyperparathyroidism. METHODS:This study retrospectively assessed cost per bioche...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.826665

    authors: Belozeroff V,Lee A,Tseng S,Chiroli S,Campbell JD

    更新日期:2013-09-01 00:00:00

  • Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.

    abstract:OBJECTIVES:The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. METHODS:Data fr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696990903438617

    authors: Bruyère O,Scholtissen S,Neuprez A,Hiligsmann M,Toukouki A,Reginster JY

    更新日期:2009-01-01 00:00:00

  • Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.

    abstract:OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.667027

    authors: Ivanova JI,Bergman RE,Birnbaum HG,Phillips AL,Stewart M,Meletiche DM

    更新日期:2012-01-01 00:00:00

  • Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.

    abstract:OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1061533

    authors: Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

    更新日期:2015-01-01 00:00:00

  • Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.

    abstract:OBJECTIVE:Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS:A Markov cohort model reproducing the natural history of HPV inf...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.490481

    authors: Demarteau N,Standaert B

    更新日期:2010-01-01 00:00:00

  • Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.

    abstract:OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1840180

    authors: Marsà A,Ascanio M,Diaz-García J,Darbà J

    更新日期:2020-11-02 00:00:00

  • Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures.

    abstract:OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1017503

    authors: Martyn D,Kocharian R,Lim S,Meckley LM,Miyasato G,Prifti K,Rao Y,Riebman JB,Scaife JG,Soneji Y,Corral M

    更新日期:2015-06-01 00:00:00

  • Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.

    abstract::Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1730123

    authors: Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

    更新日期:2020-06-01 00:00:00

  • Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.

    abstract:BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1116992

    authors: Goeree R,Goeree J

    更新日期:2016-01-01 00:00:00